PHAXIAM Therapeutics SA (XPAR:PHXM)
€ 3.04 0.01 (0.33%) Market Cap: 18.47 Mil Enterprise Value: -3.33 Mil PE Ratio: 3.10 PB Ratio: 0.50 GF Score: 38/100

Q4 2021 Erytech Pharma SA Earnings Call Transcript

Mar 14, 2022 / 12:30PM GMT
Release Date Price: €15.1 (+8.63%)
Operator

Good day and thank you for standing by. Welcome to the ERYTECH business update and financial highlights for the fourth-quarter and full-year 2021 conference call. (Operator Instructions) Please be advised today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your host today, CEO, Gil Beyen. Please go ahead.

Gil Beyen
ERYTECH Pharma S.A. - CEO

Thank you, Michelle. Good afternoon, good morning, bonjour a tous. Thank you for joining us for our business and financial update for the fourth-quarter and the full-year 2021 with key highlights and key financials for the year '21. We announced our business and financial update on Friday evening, and the press release and the webcast presentation can be found on the Investors Relations page of our website.

Joining me on the call here today are Dr. Iman El-Hariry, our Chief Medical Officer; and Eric Soyer, our Chief Financial and Chief Operating Officer.

Before starting, and I'm on slide 2 of the deck, I would like to draw your attention

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot